MannKind Corp. (MNKD)
3.85
-0.10
(-2.53%)
USD |
NASDAQ |
Nov 20, 16:00
3.93
+0.08
(+2.08%)
After-Hours: 20:00
MannKind Research and Development Expense (TTM) : 77.18M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 77.18M |
| June 30, 2026 | 76.88M |
| March 31, 2026 | 72.56M |
| December 31, 2025 | 66.35M |
| September 30, 2025 | 49.90M |
| June 30, 2025 | 48.76M |
| March 31, 2025 | 46.90M |
| December 31, 2024 | 45.89M |
| September 30, 2024 | 43.99M |
| June 30, 2024 | 41.05M |
| March 31, 2024 | 35.69M |
| December 31, 2023 | 31.28M |
| September 30, 2023 | 29.20M |
| June 30, 2023 | 23.35M |
| March 31, 2023 | 21.79M |
| December 31, 2022 | 19.72M |
| September 30, 2022 | 16.45M |
| June 30, 2022 | 15.97M |
| March 31, 2022 | 13.41M |
| December 31, 2021 | 12.31M |
| September 30, 2021 | 9.971M |
| June 30, 2021 | 7.80M |
| March 31, 2021 | 6.935M |
| December 31, 2020 | 6.248M |
| September 30, 2020 | 6.724M |
| Date | Value |
|---|---|
| June 30, 2020 | 6.82M |
| March 31, 2020 | 6.988M |
| December 31, 2019 | 6.90M |
| September 30, 2019 | 5.962M |
| June 30, 2019 | 6.425M |
| March 31, 2019 | 7.76M |
| December 31, 2018 | 8.737M |
| September 30, 2018 | 11.16M |
| June 30, 2018 | 13.48M |
| March 31, 2018 | 13.64M |
| December 31, 2017 | 14.12M |
| September 30, 2017 | 12.17M |
| June 30, 2017 | 11.03M |
| March 31, 2017 | 12.26M |
| December 31, 2016 | 14.35M |
| September 30, 2016 | 19.01M |
| June 30, 2016 | 20.69M |
| March 31, 2016 | 24.16M |
| December 31, 2015 | 28.41M |
| September 30, 2015 | 39.75M |
| June 30, 2015 | 54.63M |
| March 31, 2015 | 84.21M |
| December 31, 2014 | 100.93M |
| September 30, 2014 | 112.35M |
| June 30, 2014 | 119.86M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| United Therapeutics Corp. | 703.20M |
| ACADIA Pharmaceuticals, Inc. | 319.46M |
| Alnylam Pharmaceuticals, Inc. | 1.559B |
| Anika Therapeutics, Inc. | 28.40M |
| Savara, Inc. | 91.20M |